고환암 치료제 시장 규모, 점유율, 동향 분석 보고서 : 약물 종류별, 질환 유형별, 유통 채널별, 지역별, 부문별 예측(2025-2033년)

Testicular Cancer Drugs Market Summary

The global testicular cancer drugs market size was estimated at USD 1.08 billion in 2024 and is projected to reach USD 1.97 billion by 2033, growing at a CAGR of 6.9% from 2025 to 2033. The market is primarily driven by improved healthcare infrastructure and access, especially in emerging markets.

Growing awareness, early diagnosis, and advancements in targeted therapies and immunotherapies are boosting treatment adoption. As per the Cancer Council, approximately 1,026 individuals were diagnosed with testicular cancer in 2024, making it the most common cancer in men aged 20-39, excluding non-melanoma skin cancer. The average age at diagnosis is around 36 years. Advancements in treatment modalities, including chemotherapy, radiation therapy, and emerging targeted therapies, have significantly improved patient outcomes, contributing to the market's expansion. In addition, increased awareness and early detection through enhanced diagnostic techniques have led to better prognosis rates, further driving the demand for testicular cancer drugs.

Testicular cancer is the most common solid malignancy affecting individuals with testicles aged 15-44 years, though it accounts for only 1-2% of all tumors in males across all age groups. The vast majority of these cancers, approximately 95%, are testicular germ cell tumors (TGCTs), which form the primary focus of both clinical research and treatment efforts. TGCTs are of particular concern because they typically affect younger men during a highly productive stage of life, creating significant physical, emotional, and social impacts. Advances in surgical techniques, chemotherapy, radiation therapy, and, more recently, targeted and immunotherapies have markedly improved survival rates. Yet, challenges remain in optimizing treatment to minimize long-term side effects such as fertility issues and cardiovascular complications. Early detection is critical, allowing for less aggressive treatment approaches and improving overall prognosis. In addition, research into molecular and genetic markers is helping to refine risk stratification and tailor therapies to individual patients, supporting the broader shift toward personalized medicine in testicular cancer care. Overall, the predominance of TGCTs among young men underscores the importance of continued innovation in diagnosis, treatment, and survivorship support to address both clinical outcomes and quality-of-life considerations.

Global Testicular Cancer Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global testicular cancer drugs market report based on drug class, disease type, distribution channel, and region:

• Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
• Platinum Compounds (DNA Crosslinkers)
• Alkylating Agents
• Topoisomerase II Inhibitors
• Antitumor Antibiotics
• Vinca Alkaloids
• Others
• Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
• Seminoma
• Non-Seminomatous Germ Cell Tumors
• Refractory / Relapsed Testicular Cancer
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug class
  • 1.2.2. Disease type
  • 1.2.3. Distribution channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug class outlook
  • 2.2.2. Disease type outlook
  • 2.2.3. Distribution channel outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Testicular Cancer Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Testicular Cancer Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Testicular Cancer Drugs Market: Pipeline Analysis

Chapter 4. Testicular Cancer Drugs Market: Drug Class Estimates & Trend Analysis

• 4.1. Drug Class Segment Dashboard
• 4.2. Testicular Cancer Drugs Market: Drug Class Movement Analysis
• 4.3. Global Testicular Cancer Drugs Market Size & Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
  • 4.3.1. Platinum Compounds (DNA Crosslinkers)
    • 4.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.3.2. Alkylating Agents
    • 4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.3.3. Topoisomerase II Inhibitors
    • 4.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.3.4. Antitumor Antibiotics
    • 4.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.3.5. Vinca Alkaloids
    • 4.3.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.3.6. Others
    • 4.3.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Testicular Cancer Drugs Market: Disease Type Estimates & Trend Analysis

• 5.1. Disease Type Segment Dashboard
• 5.2. Testicular Cancer Drugs Market: Disease Type Movement Analysis
• 5.3. Global Testicular Cancer Drugs Market Size & Trend Analysis, by Disease Type, 2021 to 2033 (USD Million)
  • 5.3.1. Seminoma
    • 5.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.2. Non-Seminomatous Germ Cell Tumors
    • 5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.3. Refractory / Relapsed Testicular Cancer
    • 5.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Testicular Cancer Drugs Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Distribution Channel Segment Dashboard
• 6.2. Testicular Cancer Drugs Market: Distribution Channel Movement Analysis
• 6.3. Global Testicular Cancer Drugs Market Size & Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 6.3.1. Hospital Pharmacies
    • 6.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.3.2. Retail Pharmacies
    • 6.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.3.3. Online Pharmacies
    • 6.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Testicular Cancer Drugs Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market Share Analysis, 2024 & 2033
• 7.3. Testicular Cancer Drugs Market by Region: Key Takeaways
• 7.4. North America
  • 7.4.1. U.S.
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. Canada
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. Mexico
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. Germany
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. Spain
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Norway
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.7. Sweden
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Regulatory framework/ reimbursement structure
    • 7.5.7.3. Competitive scenario
    • 7.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Regulatory framework/ reimbursement structure
    • 7.5.8.3. Competitive scenario
    • 7.5.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Japan
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. China
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. India
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.4. Australia
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.6. Thailand
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Argentina
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. MEA
  • 7.8.1. South Africa
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.3. UAE
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework/ reimbursement structure
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.4. Kuwait
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Regulatory framework/ reimbursement structure
    • 7.8.4.3. Competitive scenario
    • 7.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company heat map analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. Bristol-Myers Squibb Company
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Pfizer Inc.
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Baxter.
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Recordati Industria Chimica e Farmaceutica S.p.A
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Teva Pharmaceutical Industries Ltd.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Fresenius SE & Co. KGaA
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Sagent
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Viatris Inc.
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Sun Pharmaceutical Industries Ltd.
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Hikma Pharmaceuticals PLC
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives
  • 8.4.11. Sandoz Group AG
    • 8.4.11.1. Company overview
    • 8.4.11.2. Financial performance
    • 8.4.11.3. Product benchmarking
    • 8.4.11.4. Strategic initiatives